Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (161-170 of 207) with videos related to

Pageof 21
Sort By:
Plos One|June 11, 2025
Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH)Pedro Cahn, Luis Barreto, Maria Ines Figueroa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 21, 2012
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsCalvin J Cohen, Jean-Michel Molina, Pedro Cahn, et al.
Journal of the International AIDS Society|July 14, 2015
Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the CaribbeanGabriela Carriquiry, Valeria Fink, John Robert Koethe, et al.
Scientific Reports|February 15, 2019
Impact of HIV-ART on the restoration of Th17 and Treg cells in blood and female genital mucosaMaría Paula Caruso, Juliana Falivene, María Pía Holgado, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2025
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE StudyMaria Ines Figueroa, Carlos Brites, Diego Cecchini, et al.
European Journal of Immunology|June 6, 2015
HIV-TB coinfection impairs CD8(+) T-cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responsesGuadalupe V Suarez, Matías T Angerami, María B Vecchione, et al.
The New England Journal of Medicine|March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Judith Aberg, Gilles Pialoux, et al.
The Journal of Infectious Diseases|August 23, 2003
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 TrialUlrik Bak Dragsted, Jan Gerstoft, Court Pedersen, et al.
Plos One|September 16, 2014
Use of third line antiretroviral therapy in Latin AmericaCarina Cesar, Bryan E Shepherd, Cathy A Jenkins, et al.
Journal of the International AIDS Society|August 12, 2011
Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconvertersM Eugenia Socías, Omar Sued, Natalia Laufer, et al.
Pageof 21

Showing results (161-170 of 207) with videos related to

Sort By:
Pageof 21
Plos One|June 11, 2025
Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH)Pedro Cahn, Luis Barreto, Maria Ines Figueroa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 21, 2012
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsCalvin J Cohen, Jean-Michel Molina, Pedro Cahn, et al.
Journal of the International AIDS Society|July 14, 2015
Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the CaribbeanGabriela Carriquiry, Valeria Fink, John Robert Koethe, et al.
Scientific Reports|February 15, 2019
Impact of HIV-ART on the restoration of Th17 and Treg cells in blood and female genital mucosaMaría Paula Caruso, Juliana Falivene, María Pía Holgado, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2025
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE StudyMaria Ines Figueroa, Carlos Brites, Diego Cecchini, et al.
European Journal of Immunology|June 6, 2015
HIV-TB coinfection impairs CD8(+) T-cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responsesGuadalupe V Suarez, Matías T Angerami, María B Vecchione, et al.
The New England Journal of Medicine|March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Judith Aberg, Gilles Pialoux, et al.
The Journal of Infectious Diseases|August 23, 2003
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 TrialUlrik Bak Dragsted, Jan Gerstoft, Court Pedersen, et al.
Plos One|September 16, 2014
Use of third line antiretroviral therapy in Latin AmericaCarina Cesar, Bryan E Shepherd, Cathy A Jenkins, et al.
Journal of the International AIDS Society|August 12, 2011
Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconvertersM Eugenia Socías, Omar Sued, Natalia Laufer, et al.
Pageof 21